12 unchanged sentences
None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10 percent or more of our common stock or to any of our affiliates.
−Removed: As of March 31, 2022, we had used approximately $5.1 of the net proceeds from our initial public offering for the development of AGENT-797 and working capital and other general corporate purposes.
+Added: As of June 30, 2022, we had used approximately $10.0 of the net proceeds from our initial public offering for the development of AGENT-797 and working capital and other general corporate purposes.
There has been no material change in our planned use of the net proceeds from the offering as described in our Registration Statement on Form S-1.
+Added: Amended and Restated Intercompany Services Agreement, by and between Agenus Inc.
+Added: and MiNK Therapeutics, Inc., dated August 2, 2022, with effect April 1, 2022.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
MiNK Therapeutics, Inc.
+Added: August 15, 2022
/s/ Jennifer S.
President and Chief Executive Officer (Principal Executive Officer)
+Added: August 15, 2022
/s/ Christine M.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.